Alexion Pharmaceuticals Inc. Stock, NASDAQ:ALXN
121 Seaport Boulevard, Boston, Massachusetts 02210
United States of America
Number of Employees: 3837
Alexion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.